Rapid Response Revival launches Series E Capital Raise to raise $5m and executes agreement with a global electronics manufacturer for production of the CellAED® in Taiwan

Rapid Response Revival launches Series E Capital Raise to raise up to $5m to provide working capital, funding the company’s first in-human trial of the CellAED and to fund the initial manufacture, distribution and sales into the New Zealand market.

The capital raise will progress the company into commercialisation phase.

The offer is of up to 55,555 ordinary shares at a price of $90 per share, which values the company at $102m.

Rapid Response Revival Research Limited has finalised an agreement with a global Original Equipment Manufacturer (OEM),  enabling manufacturing capabilities to produce the CellAED^®  in Taiwan from July this year.

This was the culmination of twelve months of work with the OEM, and is a significant step forward on our journey. The agreement gives Rapid Response Revival Research Limited the ability to produce the CellAED^®  in significant volumes and also brings the benefit of pricing power in the procurement of components, which will help lower the costs of production.

The OEM is the subsidiary of a Taiwanese multi-national electronics manufacturer with over 75,000 employees globally and annual revenues of over US$8bn, producing large volumes of medical devices, thermal control, imaging, X-ray and other electronic devices annually and is a global leader in the field.  Assistance with distribution in Taiwan and other nearby areas will also be provided by the company, as part of a hugely valuable relationship and partnership for RRR.

Register Interest

About Rapid Response Revival Research Limited

Rapid Response Revival are the innovators behind the CellAED^® defibrillator technology – transforming everyday people into heroes.

Sudden Cardiac Arrest (SCA) has an extremely high death rate and is a leading cause of death globally, accounting for more deaths than many cancers, influenza, car accidents and house fire deaths combined. Anyone can suffer from SCA, regardless of age, gender or fitness level – including children. The current survival rate is just 2-11%.

The CellAED^® is designed to assist everyday people and medical professionals to prevent many unnecessary deaths. It is a lightweight, affordable, and personal Automated External Defibrillator (AED) solution, targeting the current government and enterprise market as well as the personal and home AED market.

Register Interest